[ad_1]
Since i know began to develop the first trimester, is considered by many the most effective vaccine of those that are being manufactured in the world. The vaccine that the University of Oxford is developing together with the AstraZeneca laboratory, and which is already in phase 3 testing in various parts of the world, he should have stopped his rehearsals, following suspicion of a serious adverse reaction in a volunteer in the UK.
An AstraZeneca spokesperson said in a statement that the “The company’s standard review process caused a pause in vaccination to allow review of safety data”.
It was not clear if the suspension of the trials was due to any regulator, although it is estimated that AstraZeneca did so voluntarily and not ordered by any regulatory agency.
The characteristics of the adverse reaction and when it happened, are still unknown, although the participant is expected to recover, according to a person familiar with the matter, according to the Stat portal.
The spokesperson described the break as “A routine action that you must always perform there is a potentially unexplained illness in one of the trials, while it is being investigated, ensuring that we maintain the integrity of the evidence. “
For now the rehearsals only they would have been suspended in Great Britain and the USA, and not in other countries like South Africa or Brazil, where tests are also being carried out, but they are already being evaluated to stop them as well.
The vaccine would be the first to start its trials in Chile, in a test that would start on September 14 and that it would take place at the Las Condes Clinic, with the collaboration of the University of Chile.
However, from the clinic they point out that they have not yet been informed about this incident in Great Britain, so it is too early to venture what will happen with the rehearsal that should start next week.
The incident not only generated an alert on the coronavirus vaccine. According to Stat, another AstraZeneca official noted that the incident led to the lab stopped other vaccines being developedIt even raised concern in the clinical trials being conducted by other vaccine manufacturers.
For a vaccine to fail at this stage of testing is not unusual, on the contrary, it is more likely to happen. As Minister Andrés Couve pointed out in an interview with La Tercera on August 1, only 17% of vaccines that are in phase 3 testing, according to estimates by the World Health Organization (WHO), they end successfully.
[ad_2]
